William Blair Forecasts Exelixis’ Q1 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at William Blair lifted their Q1 2025 earnings estimates for shares of Exelixis in a research report issued on Tuesday, February 11th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will earn $0.40 per share for the quarter, up from their previous estimate of $0.39. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share.

A number of other research firms have also recently commented on EXEL. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday. Brookline Capital Management initiated coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $30.00 to $40.00 in a research report on Monday, January 27th. Stifel Nicolaus increased their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday. Finally, Citigroup boosted their price objective on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Exelixis Trading Up 1.5 %

Shares of EXEL opened at $35.00 on Friday. The firm has a market cap of $10.00 billion, a PE ratio of 22.44, a P/E/G ratio of 0.63 and a beta of 0.53. Exelixis has a 1-year low of $20.14 and a 1-year high of $37.59. The firm has a fifty day simple moving average of $34.19 and a two-hundred day simple moving average of $30.83.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%.

Institutional Investors Weigh In On Exelixis

A number of hedge funds have recently bought and sold shares of the business. Seizert Capital Partners LLC raised its position in shares of Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after buying an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock valued at $1,424,000 after purchasing an additional 20,641 shares during the period. Tri Ri Asset Management Corp bought a new stake in shares of Exelixis in the 3rd quarter valued at approximately $4,396,000. Finally, CWA Asset Management Group LLC purchased a new position in shares of Exelixis in the 3rd quarter worth approximately $577,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares in the company, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the transaction, the executive vice president now owns 278,665 shares of the company’s stock, valued at $9,828,514.55. This represents a 3.46 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,588 shares of company stock valued at $3,981,864. Corporate insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.